Endo Pharmaceuticals (Nasdaq: ENDP) announced topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points…
Back Pain News From Medical News Today Tags: announces, Axomadol, back, chronic, Endo, from, pain, Phase, Results, study, Topline
This entry was posted on November 28, 2011 at 5:14 am and is filed under Blood. You can follow any responses to this entry through the RSS 2.0 feed.
